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A B S T R A C T   
Nicotinamide adenine dinucleotide (NAD+) plays a fundamental role in life and health through the regulation of 
energy biogenesis, redox homeostasis, cell metabolism, and the arbitration of cell survival via linkages to 
apoptosis and autophagic pathways. The importance of NAD+ in ageing and healthy longevity has been revealed 
from laboratory animal studies and early-stage clinical testing. While basic researchers and clinicians have in-
vestigated the molecular mechanisms and translation potential of NAD+, there are still major gaps in applying 
laboratory science to design the most effective trials. This mini-review was based on the programme and dis-
cussions of the 3rd NO-Age Symposium held at the Akershus University Hospital, Norway on the 28th October 
2019. This symposium brought together leading basic researchers on NAD+ and clinicians who are leading or 
are going to perform NAD+ augmentation-related clinical studies. This meeting covered talks about NAD+ 
synthetic pathways, subcellular homeostasis of NAD+, the benefits of NAD+ augmentation from maternal milk 
to offspring, current clinical trials of the NAD+ precursor nicotinamide riboside (NR) on Ataxia-Telangiectasia 
(A-T), Parkinson’s disease (PD), post-sepsis fatigue, as well as other potential NR-based clinical trials. 
Importantly, a consensus is emerging with respect to the design of clinical trials in order to measure meaningful 
parameters and ensure safety.   
1. Introduction 
Ageing is a natural process which is increasingly being dissected for 
mechanisms that could be targeted with the hope of delaying or 
limiting the rapid functional decline in resiliency seen in old age (Fang 
et al., 2015; Partridge et al., 2018). In order to address the global 
healthcare and socio-economic issues that are becoming apparent as 
medical advances extend human lives, research is aimed at exploring 
https://doi.org/10.1016/j.mad.2020.111208 
Received 4 December 2019; Received in revised form 10 January 2020; Accepted 13 January 2020    
⁎ Corresponding author at: Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway. 
E-mail address: e.f.fang@medisin.uio.no (E.F. Fang). 
1 Equal contribution. 
Mechanisms of Ageing and Development 186 (2020) 111208
Available online 15 January 2020
0047-6374/ © 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
possible transformative interventional strategies and molecules that 
target ageing and age-predisposed diseases (Bakula et al., 2018;  
Campisi et al., 2019; Fang et al., 2016b; Kennedy et al., 2014; Lopez- 
Otin et al., 2013; Rubinsztein et al., 2011; Singh et al., 2019). Recently, 
nicotinamide adenine dinucleotide (NAD+) has entered the spotlight in 
ageing research, leading to many attempts to harness the potential of 
NAD+ and its precursors for use in the clinic. NAD+ coenzymes are the 
central catalysts of metabolism in all living cells, serving as critical 
components in energy production, metabolic transformations, detox-
ification of reactive oxygen species, and as a substrate for enzymes such 
as the PARPs, Sirtuins (SIRTs), CD38/CD157, and SARM1 (Bogan and 
Brenner, 2008; Canto et al., 2015; Fang et al., 2017; Lautrup et al., 
2019c; Verdin, 2015; Yoshino et al., 2018). 
Over the last decade, the importance of NAD+ in healthy ageing and 
longevity has been recognised, detailed molecular mechanisms un-
veiled, and many clinical trials explored. Studies from laboratory ani-
mals, such as in nematodes and mice, and in human primary cells and 
post-mortem tissues, as well as human brain imaging, indicate that 
there is an age-dependent reduction of NAD+ in cells and tissues (Fang 
et al., 2016a, 2014; Gomes et al., 2013; Hou et al., 2018; Lautrup et al., 
2019c; Mouchiroud et al., 2013; Zhu et al., 2015). Mechanistically, it is 
suggested that ageing-induced NAD+ reduction may result from re-
duced production – as there is an age-dependent reduction of key en-
zymes involved in NAD+ metabolism – or increased consumption by 
NAD+-consuming enzymes, such as PARPs, CD38, and Sirtuins 
(Camacho-Pereira et al., 2016; Fang et al., 2016a, 2014; Lautrup et al., 
2019c; Mouchiroud et al., 2013; Scheibye-Knudsen et al., 2014; Verdin, 
2015). All three classes of enzymes compete for NAD+ during ageing, 
ultimately leading to a bioavailability level insufficient to sustain all 
NAD+-requiring cellular activities. Intriguingly, NAD+ repletion, by 
the supplementation of NAD+ precursors, such as nicotinamide ribo-
side (NR) (Bieganowski and Brenner, 2004), nicotinamide mono-
nucleotide (NMN), nicotinamide (NAM), or even NAD+ itself, delay 
ageing phenotypes and promote healthy longevity in both normal and 
accelerated ageing models in Caenorhabditis elegans (roundworms), 
Drosophila melanogaster (fruit flies), and mice (de Picciotto et al., 2016;  
Fang et al., 2019a, b; Fang et al., 2016a, 2014; Frederick et al., 2016;  
Gomes et al., 2013; Mills et al., 2016; Mitchell et al., 2018; Mouchiroud 
et al., 2013). Encouraged by animal studies, more than 20 clinical 
studies exploring whether NR may alleviate pathological ageing and 
age-predisposed diseases have been initiated. At least 5 clinical trials 
have been completed showing that 1−2 g/day of NR for up to 1–3 
months is safe, as summarised recently (Lautrup et al., 2019c). While 
there were encouraging results in some NR-based phase 1 clinical trials 
aiming to reduce blood pressure in healthy middle-aged and older 
adults (Martens et al., 2018) and to slow disease progression in 
amyotrophic lateral sclerosis (ALS) (NR + pterostilbene) (de la Rubia 
et al., 2019), no effect was reported in trials of short-term (up to 2–3 
months) NR supplementation in obese, insulin-resistant men (Dollerup 
et al., 2018) and nondiabetic males with obesity (Dollerup et al., 2019), 
nor in muscle-mitochondrial bioenergetics in aged men (Dollerup et al., 
2019). Of note, all three reports were from the same study and reported 
different outcomes from the same set of obese men (NCT02303483). 
Possible considerations include a much higher dose of NR (2 g/day) 
than other trials (mostly 1 g/day) and a different NAD+ detection 
method. Thus, these studies emphasise some of the challenges with 
clinical trials of NAD+-boosting compounds with regards to dose and 
assessment of NAD+ bioavailability. 
The Norwegian Centre on Healthy Ageing (NO-Age) aims to estab-
lish a multi-disciplinary research network to address the challenges of 
ageing and to foster translational studies to promote healthy ageing, 
healthy lifestyles and social participation in old age (Fang et al., 2019c). 
On the 28th of October 2019, the 3rd NO-Age Symposium took place, 
covering NAD+ in depth: from biochemistry to clinical trials. The event 
was hosted at the Akershus University Hospital (Ahus, Lørenskog, 
Norway), and was organised by Evandro F. Fang, Hilde Nilsen, Linda 
Bergersen and Jon Storm-Mathisen, founding members of the NO-Age 
network. Here we provide a summary of the main points of the sym-
posium. 
2. An overview of the meeting 
2.1. The basics of NAD+ 
NAD+ has a central function in metabolism, where it functions in 
redox reactions. NAD+ switches back and forth between its reduced 
(NADH), and oxidised forms (NAD+). NAD+ is reduced to NADH 
during catabolic processes – the burning of fats, carbohydrates, and 
proteins, while its reduced counterpart is used for anabolic purposes – 
building new molecules such as ATP, glucose, and ketone bodies (Bogan 
and Brenner, 2008; Lautrup et al., 2019c). NAD+ is also important as a 
substrate or coenzyme in certain non-redox reactions involved in sev-
eral cellular processes including, but not limited to: pathways central in 
ageing, DNA repair, calcium signalling and gene regulation (Camacho- 
Pereira et al., 2016; Fang et al., 2016a, 2014; Lautrup et al., 2019c;  
Mouchiroud et al., 2013; Verdin, 2015). 
Charles Brenner, the keynote speaker from the University of Iowa 
(Iowa, USA), started his lecture by explaining why we need a broader 
definition of metabolism. This argument is clearly emphasised by 
NAD+ having functions reaching far beyond anabolism and catabolism. 
Since his discovery of NR as an NAD+ precursor in 2004 (Bieganowski 
and Brenner, 2004), Brenner has expanded his research on NAD+ from 
metabolism to biomarker development and clinical trials for a broad 
variety of diseases. Failing metabolic homeostasis is observed in chronic 
heart failure (Diguet et al., 2018), Brenner and co-workers therefore 
investigated the expression of NAD+ biosynthetic enzymes in a mouse 
model of dilated cardiomyopathy and found a 30 % decrease in NAD+ 
levels, a downregulated recycling enzyme, and an upregulation of ni-
cotinamide riboside kinase 2 (NRK2) (Diguet et al., 2018). By supple-
menting the mice with nicotinamide riboside (NR) they showed in-
creased levels of NAD+ and several of its metabolites, which helped to 
stabilise their metabolism and attenuated the development of heart 
failure in a mouse model of dilated cardiomyopathy (Diguet et al., 
2018). 
Another metabolic stressor found to challenge the NAD+ metabo-
lome is the postpartum period. A recent study by the Brenner group 
shows that postpartum rats have a suppressed NAD+ metabolome in 
the liver (Ear et al., 2019). Furthermore, raised blood levels of NAD+ 
were found, increasing the levels of NAD+ in the mammary glands at 
the liver’s expense. By supplementing the mothers with NR, Brenner 
and colleagues observed improved nursing behaviour and nutrient 
transfer to the pups (Ear et al., 2019). Several positive, lasting changes 
in neurodevelopment and metabolic parameters were also noted (Ear 
et al., 2019). Brenner's experiment is one of many showing how stres-
sors can affect the NAD+ pool at a physiological level. NAD+ seems to 
be redirected or shuttled to areas with high metabolic demand. 
Elucidating just how dynamic the flux of NAD+ is on a cellular level 
has been a focus in recent work of Mathias Ziegler from the University 
of Bergen (Bergen, Norway), who has developed tools to identify the 
intracellular pools of NAD+. NAD+ is found in the mitochondria, nu-
cleus, Golgi apparatus, peroxisomes and in the endoplasmic reticulum 
(ER) and there is a balance of NAD+ between the different sub-cellular 
compartments (Lautrup et al., 2019c; Stromland et al., 2019). By se-
lectively depleting cell compartments of NAD+ with an EGFP-PARP1cd 
(the PARAPLAY system (Dolle et al., 2010)), Ziegler can examine the 
resulting effects on a single-compartment basis (VanLinden et al., 2015,  
2017). By tracking the formation of NAD+ from stable isotope-labelled 
NAD+ precursors and simultaneously monitoring the disappearance of 
unlabelled NAD+, it is possible to determine cellular NAD+ turnover 
rates. Thereby, the impact of cellular insults on compartmental NAD+ 
metabolism can be established, even if the NAD+ concentration itself 
remains unchanged. Despite having a rather large NAD+ pool, 
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mitochondria are sensitive to direct changes to their NAD+ availability, 
both through depletion and satiety, and compensate by redistributing 
NAD+ from the cytosol to mitochondria. Mitochondria appear to play 
an important role in supporting NAD+-dependent processes throughout 
the cells under conditions that are accompanied by NAD+ depletion 
(VanLinden et al., 2015; Yang et al., 2007). 
2.2. NAD+ in accelerated ageing and age-predisposed neurodegeneration 
Hilde Nilsen from Ahus and UiO (Oslo, Norway) shared her un-
derstanding of NAD+ in Ataxia-Telangiectasia (A-T), a rare disease with 
features of premature ageing caused by defects in DNA repair (Fang 
et al., 2016b; Shiloh and Lederman, 2017; Shiloh and Ziv, 2013). Key 
features of A-T include impaired coordination of muscle movements, 
telangiectasia, cancer predisposition, sensitivity to DNA damaging 
agents (especially DNA double-strand break inducers), im-
munodeficiency, vestigial thymus and gonads, endocrine abnormalities, 
as well as neurodegeneration (Shiloh and Lederman, 2017). The ma-
jority of the A-T phenotypes can be explained by an impaired DNA 
damage response due to mutations in the gene ATM which encodes 
ATM (Shiloh and Ziv, 2013); Vilhelm Bohr and Evandro Fang, in col-
laboration with the Nilsen group and others, reported that a sustained 
DNA damage response drove NAD+ depletion in ATM-defective animal 
models, leading to mitochondrial dyshomeostasis and progressive 
neuronal loss (Croteau et al., 2017; Fang and Bohr, 2017; Fang et al., 
2016a). In this study using C. elegans, Nilsen provided experimental 
evidence that hyper-PARylation consumes NAD+ in atm-mutant ne-
matodes. Moreover, it was demonstrated that augmentation of NAD+ 
levels through NR supplementation, PARP inhibition, or Sir2.1 activa-
tion, improved healthspan and extended lifespan in the mutants 
(Croteau et al., 2017; Fang and Bohr, 2017; Fang et al., 2016a). These 
findings were conserved from worms to mice, indicating the potential 
for therapeutic intervention in A-T. 
Sofie Lautrup from Ahus and UiO (Oslo, Norway) presented a study 
on the autosomal recessive accelerated-ageing disorder Werner syn-
drome (WS), a classical DNA repair impairment-oriented premature 
ageing disease. From their second and third decade of life, WS patients 
develop a relatively short stature, display greying and loss of hair, 
prematurely aged faces, and juvenile cataracts, and are predisposed to 
cancer, dyslipidemia, premature atherosclerosis, and insulin-resistant 
diabetes (Oshima et al., 2017; Shamanna et al., 2017; Takemoto et al., 
2013). Several major features of WS can be explained by a DNA repair 
deficiency caused by mutations in the gene encoding the Werner pro-
tein (WRN), an important DNA repair protein with unique helicase and 
exonuclease activities (Chan et al., 2019; Shamanna et al., 2016; Yu 
et al., 1996; Zhang et al., 2015). However, the molecular mechanisms 
underlying severe dysregulation of energy metabolism in WS is still not 
fully understood (Takemoto et al., 2013). Drs. Evandro Fang and Vil-
helm Bohr led a project with data showing reduced NAD+ levels in WS 
patients and WS worms, possibly due to increased cellular NAD+ con-
sumption by the PARPs, and reduced NAD+ production as evidenced by 
a decline in the levels of NMNAT1, which converts NMN to NAD+ 
(Fang et al., 2019a). The D. melanogaster WRN is a 353 amino acid 
protein with only the exonuclease domain (Cox et al., 2007; Lautrup 
et al., 2019a). Lautrup and colleagues showed that the knockdown of 
WRNexo gene mutation of WRN in flies resulted in a short lifespan and 
impaired proliferation of intestinal stem cells (ISCs); NAD+ augmen-
tation by supplying either NR or NMN was able to extend lifespan in 
both WRNexo knockdown and WT flies, as well as restoring pro-
liferative capacity of ISCs in the WRNexo knockdown flies (Fang et al., 
2019a). NAD+ augmentation also improved mitochondrial homeostasis 
and metabolism in both WS patient cells and WS animal models. Such 
data suggest reduced cellular NAD+ is a likely player in WS pathology, 
highlighting targeting of the NAD+ pool as an interventional target for 
WS patients. A clinical study in Werner patients is underway. 
Yahyah Aman from Ahus and UiO (Oslo, Norway) presented on the 
potential uses of NAD+ precursors in delaying the progression of 
Alzheimer’s disease (AD). Although AD is most often characterised by 
accumulation of amyloid-β (Aβ) plaques and tau tangles, therapies 
targeting these proteinaceous deposits have given disappointing results 
in clinical trials, thus, there is a drive to develop novel therapeutic al-
ternatives (Cummings et al., 2018; Kerr et al., 2017). Along with Aβ and 
tau, damaged mitochondria accumulate in the neurons of AD patients; a 
common pathological phenomenon partially due to compromised mi-
tophagy (Fang, 2019; Fang et al., 2019b; Kerr et al., 2017; Lautrup 
et al., 2019b). Indeed, impaired mitophagy in AD was observed in 
human post-mortem tissue and in both iPSCs and animal models of AD. 
Moreover, pharmacological (including the use of NAD+ precursors) and 
genetic promotion of mitophagy alleviated memory loss in Aβ1-42 
(CL2355) AD worms, tau (BR5270) AD worms, APP/PS1 AD mice and 
3xTg AD mice (Fang et al., 2019b). The underlying mechanisms of 
NAD+-regulated mitophagy have been summarised by the Fang group 
elsewhere (Fang, 2019). Aman is now working on understanding the 
molecular mechanisms of how mitophagy eliminates p-tau in different 
laboratory model systems. 
2.3. Clinical trials 
Norway is being put on the map as a small country with an intense 
interest in NAD+ precursors. Several clinical trials are either ongoing or 
planned to start shortly. 
Hilde Nilsen gave an update on an open-label observation trial on 
NR supplementation in children with A-T based on the results of the 
basic research she presented (mentioned above). Norway has estab-
lished a nation-wide program for disease monitoring for this patient 
group that includes standardised longitudinal motoric testing. In this 
trial, A-T patients are given NR as a dietary supplement. Changes of 
blood NAD+ and related metabolites are monitored over a period of 
two years parallel to regular motoric testing and clinical follow-up. 
Ole-Bjørn Tysnes from NeuroSysMed, Haukeland University 
Hospital (HUH) and the University of Bergen (UiO) (Bergen, Norway) 
gave a summary on the current literature on oxidative stress, NAD+ 
reduction and ALS. Major clinical phenotypes of ALS include impair-
ment of voluntary muscle movement caused by the progressive de-
generation of motor neurons in the spinal cord, brain stem, and motor 
cortex (Tang, 2017). ALS has complicated etiologies, with mitochon-
drial dysfunction, increased oxidative stress, NAD+ reduction, and 
impaired gut microbiota proposed as being implicated in some patients' 
groups (Blacher et al., 2019; Carri et al., 2017; Lautrup et al., 2019c). A 
recent study of the long-term ALS mortality trends in Norway between 
1951 and 2014 revealed 5345 ALS deaths during this period, with a 
mean annual increase of 1.14 % (Nakken et al., 2016). Age-period-co-
hort analyses suggest that this increase was best explained by cohort 
effects due to environmental impact and improved case ascertainment. 
Recent studies link impaired NAD+ metabolism to ALS pathology. A 
study reported that enhancement of the NAD+ salvage pathway pro-
tects astrocytes expressing an ALS-linked mutant SOD1, hereby pro-
moting motor neuron survival (Harlan et al., 2016). Pharmacological 
(NR or NMN) or genetic (NAMPT overexpression) approaches to restore 
cellular NAD+ levels increased oxidative stress resistance in motor 
neurons (Harlan et al., 2019, 2016). Congruently, a recent study found 
low abundance of the protective bacterium Akkermansia muciniphila, 
associated with impaired NAD+ metabolism in ALS (Blacher et al., 
2019). Compared with healthy controls, NAM depletion was evident in 
both serum and cerebrospinal fluid (CSF) samples from ALS patients; 
accordingly, NAM supplementation dramatically improved both beha-
vioural and pathological phenotypes in ALS-prone SOD1-Tg mice 
(Blacher et al., 2019). Encouragingly, a recent preliminary clinical trial 
with EH301 (NR + pterostilbene) indicated potential benefits for ALS 
patients (de la Rubia et al., 2019). Tysnes is planning to run a similar 
trial, termed NO-ALS, from Bergen, evaluating the value of NAD+ 
augmentation in treating ALS. 
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Charalampos Tzoulis from the NeuroSysMed, Center, Haukeland 
University Hospital (HUH) and University of Bergen (UiB) (Bergen, 
Norway) gave updates on the randomised, double-blinded clinical trials 
NAD-PARK and NO-PARK. Parkinson’s disease affects ∼1.8 % of the 
population above the age of 65 years (de Rijk et al., 2000). The neu-
ropathological hallmark of PD is the progressive loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNc). Additional neuro-
degenerative changes occur in multiple regions of the nervous system 
and patients suffer progressive disability due to a combination of pro-
gressive motor impairment and non-motor dysfunction (Dickson, 
2012). 
Studies in post-mortem brain tissue from individuals with PD have 
shown impaired mitochondrial function, including complex-I deficiency 
(Flones et al., 2018) and defective mtDNA maintenance (Dolle et al., 
2016). Furthermore, similar to AD and ALS, studies in patient iPSC- 
derived dopaminergic neurons, and animals modeling aspects of PD 
pathology have shown evidence of perturbed NAD+ metabolism. 
Moreover, NAD+ augmentation improved survival of dopaminergic 
neurons in fly-based models and patient iPSC-derived dopaminergic 
neurons (Lautrup et al., 2019c; Schondorf et al., 2018). For the nearly- 
completed NAD-PARK trial, 30 PD patients were recruited at the De-
partment of Neurology, HUH, then randomly assigned (1:1) to one of 
two study groups (n = 15 per group): NR 500 mg x 2/day, or placebo 
(NCT03816020). While they are now assessing the results of NAD- 
PARK, Tzoulis is leading the phase 2 clinical trial (NO-PARK) where 
they are recruiting 400 patients with newly diagnosed PD and randomly 
assigning them to either NR (500 mg x 2/day) or placebo for a period of 
52 weeks (NCT03568968). 
Torbjørn Omland from Ahus and UiO (Oslo, Norway) gave a pre-
sentation of a planned clinical trial to evaluate the ability of NR to 
reduce chemotherapy-induced side effects in the cardiovascular system. 
Omland, together with Fang and Nilsen, is planning a clinical trial 
evaluating NR supplementation parallel to adjuvant therapy for breast 
cancer. Breast cancer is the most frequently occurring malignancy in 
Norwegian women, and the incidence has nearly doubled in the past 40 
years (Cancer in Norway 2016). Unfortunately, many breast cancer 
survivors suffer from treatment-induced side effects, such as heart 
failure and other manifestations of cardiovascular malfunction. There is 
a limited understanding of the molecular mechanisms driving devel-
opment of these. The study will extend and benefit from local infra-
structure built through the PRADA (PRevention of cArdiac Dysfunction 
during Adjuvant breast cancer therapy) study program that en-
compasses women with early breast cancer receiving adjuvant therapy. 
PRADA III, the NR study, aims to show if NAD+ supplementation is 
capable of reducing the side effects of cancer patients receiving che-
motherapy. The rationale for supplementing with NR is to restore 
NAD+ levels depleted following chemotherapy-induced PARP1-hyper-
activation. 
Arne Søraas from the Oslo University Hospital (OUS, Oslo, Norway) 
presented a planned clinical trial, also addressing PARP1-induced 
NAD+ depletion (NCT04110028). Arne Søraas is a post-doctoral fellow 
and project group leader at the research group for genome and epi-
genome regulation in embryo development, ageing, and disease. The 
research group studies geroscience with a translational aim and has set 
up the study in collaboration with several intensive care units at OUS to 
improve patient outcomes in the recovery phase after severe acute ill-
ness. 
Recovery is often prolonged after a severe illness in aged patients, 
and even younger patients experience fatigue which leads to lengthy 
hospital stays, incomplete recovery, and increased mortality (Boyd 
et al., 2008; Hermans et al., 2014; Iwashyna et al., 2010). Currently 
optimal care, nutrition, and mobilisation are the best options for im-
proving patient outcomes in this phase, and, to our knowledge, no 
pharmacological interventions are available. The severity of fatigue 
after acute illness is associated with the type of disease and extent of 
tissue damage suffered (Iwashyna et al., 2010). Tissue damage, usually 
caused by infections, circulation disturbances, surgery, or trauma is a 
known activator of the nuclear NAD+ consuming PARP1 pathway (Luo 
and Kraus, 2012), and the study aims to show if NAD+ augmentation is 
capable of improving patient outcome during recovery. 
In the trial it is planned that hospitalised patients will be rando-
mised into groups and given either NR or placebo when they are 
clinically stabilised and still expected to stay in the hospital for at least 
one week. The primary endpoint is the duration of hospital stay after 
randomisation. Secondary endpoints include measures of the com-
pleteness of recovery. NR will be administered over three months to 
cover the whole recovery period. NR has not been supplemented in this 
group before, and the study is also a dose-ranging study where in-
creasing doses of NR (from 250 mg to 2000 mg daily) are tested. The 
NAD+ metabolome of peripheral blood mononuclear cells will be 
measured in some of the participants, while epigenetic changes in-
cluding changes to DNA methylation clocks and biochemical status will 
be measured in all patients. 
Trygve Holmøy from Ahus and UiO (Oslo, Norway) chaired a panel 
discussion that tackled several emerging questions, spanning from how 
to determine appropriate doses of NR for clinical trials, to revealing/ 
monitoring potential side effects, to reasons for some negative NR- 
based clinical trials. There is a strong need to implement reliable bio-
markers, particularly in neurodegenerative diseases where clinical 
scoring systems are rather insensitive and require long follow-up. 
Neurofilament light chain is now emerging as a promising biomarker 
that reflects treatment effects in several neurodegenerative diseases 
(Gaetani et al., 2019). Moreover, there is a paucity of observational 
data from humans during health and disease that would allow us to 
predict potential treatment effects and thereby guide power calcula-
tions in clinical studies. Such discussions were very useful in view of the 
ongoing or planned NR-based clinical trials in Norway. 
3. Emerging questions on how to design a better clinical study 
While the majority of laboratory and clinical data suggest a strong 
translational potential for NAD+-boosting compounds, some studies 
have reported little-to-no effect, raising new questions to be addressed 
on challenges and barriers to the translation of NAD+-boosting com-
pounds. For example, negative data from the study of NR in obese men 
(NCT02303483) suggests that further considerations on dose, treatment 
period, number and diversity of the patients need to be taken into ac-
count in future clinical studies, as well as the use of sensitive and stable 
NAD+ assessment methods. In the Q&A section, major questions and 
discussions related to how best to determine appropriate doses of NR in 
clinical trials, tips for experiment design, and the optimal timeline to 
watch for NAD+-related benefits. While there has been enough data on 
the pharmacokinetics and toxicity profile of NR in the healthy elderly, it 
is conceivable that children and patients with different diseases may 
have different responses to NAD+-boosting compounds, thus in-
dependent data on pharmacokinetics and toxicity should be established 
for each specific disease and age group. Accordingly, the aetiologies of 
each disease should be carefully considered to determine the optimal 
period for NAD+-boosting, compound-based treatment. The speakers 
also recommend including ‘exercise’ and ‘exercise + NAD+ boosting 
compound’ groups since exercise may play a synergistic role in NAD+- 
related benefits to metabolism and muscle functions.’ 
4. Closing remarks 
Over the past decade, our understanding of NAD+ has expanded 
beyond its crucial role in bioenergetics and metabolism to its new role 
as a key component in healthy longevity. Growing evidence from la-
boratory animals to humans suggest an age-dependent reduction of 
NAD+, while NAD+ augmentation has been shown to improve 
healthspan and extend lifespan, as well as alleviate the symptoms of a 
broad range of age-related diseases, including AD, PD, ALS etc., in 
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laboratory animal models (Fang et al., 2017; Lautrup et al., 2019c;  
Verdin, 2015). Accordingly, several clinical trials of NR are planned or 
ongoing (https://clinicaltrials.gov/). 
Despite the optimism there are still outstanding questions in the 
field: first, further study is needed on the detailed molecular mechan-
isms and links between NAD+, healthy ageing, and longevity, including 
its neuroprotective effects. Second, the relationship between NAD+ 
reduction and ageing in a large, human population setting needs to be 
determined. Third, while NR seems to be a promising supplement in a 
wide range of diseases, we must not forget that clinical trials are still 
small and in early phases, and that possible negative long-term effects 
could still become apparent. Furthermore, the precise relationships 
between NAD+ and different cancers should be addressed, since NAD+ 
augmentation has been shown to have tumour-promoting effects in 
laboratory animal model (Demarest et al., 2019; Nacarelli et al., 2019) 
but also to inhibit breast cancer in mice (Santidrian et al., 2013) and 
skin cancers in high-risk patients (Chen et al., 2015). 
Declaration of Competing Interest 
E.F.F. and H.N., have CRADA arrangements with ChromaDex. 
E.F.F., H.N., L.H.B., J.S.M., L.J.R. are consultants to Aladdin Healthcare 
Technologies. E.F.F. is a consultant to the Vancouver Dementia 
Prevention Centre. C.B. is Chief Scientific Adviser and a stockholder of 
ChromaDex. 
Acknowledgements 
The authors acknowledge the valuable work of the many in-
vestigators whose published articles they were unable to cite owing to 
space limitations. The authors thank Dr. Vilhelm Bohr at the NIA and 
University of Copenhagen for reading of the manuscript. E.F.F. is sup-
ported by HELSE SØR-ØST (#2017056), the Research Council of 
Norway (#262175 and #277813), the National Natural Science 
Foundation of China (#81971327), an Akershus University Hospital 
Strategic grant (#269901), and a Rosa Sløyfe grant (#207819) from the 
Norwegian Cancer Society. H.N. was supported by grants from HELSE 
SØR-ØST (#2019098) and Bergesenstiftelsen. 
References 
Bakula, D., Aliper, A.M., Mamoshina, P., Petr, M.A., Teklu, A., Baur, J.A., Campisi, J., 
Ewald, C.Y., Georgievskaya, A., Gladyshev, V.N., Kovalchuk, O., Lamming, D.W., 
Luijsterburg, M.S., Martin-Montalvo, A., Maudsley, S., Mkrtchyan, G.V., Moskalev, 
A., Olshansky, S.J., Ozerov, I.V., Pickett, A., Ristow, M., Zhavoronkov, A., Scheibye- 
Knudsen, M., 2018. Aging and drug discovery. Aging (Albany NY) 10, 3079–3088. 
Bieganowski, P., Brenner, C., 2004. Discoveries of nicotinamide riboside as a nutrient and 
conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi 
and humans. Cell 117, 495–502. 
Blacher, E., Bashiardes, S., Shapiro, H., Rothschild, D., Mor, U., Dori-Bachash, M., 
Kleimeyer, C., Moresi, C., Harnik, Y., Zur, M., Zabari, M., Brik, R.B., Kviatcovsky, D., 
Zmora, N., Cohen, Y., Bar, N., Levi, I., Amar, N., Mehlman, T., Brandis, A., Biton, I., 
Kuperman, Y., Tsoory, M., Alfahel, L., Harmelin, A., Schwartz, M., Israelson, A., 
Arike, L., Johansson, M.E.V., Hansson, G.C., Gotkine, M., Segal, E., Elinav, E., 2019. 
Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 
572, 474–480. 
Bogan, K.L., Brenner, C., 2008. Nicotinic acid, nicotinamide, and nicotinamide riboside: a 
molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. 
Nutr. 28, 115–130. 
Boyd, C.M., Landefeld, C.S., Counsell, S.R., Palmer, R.M., Fortinsky, R.H., Kresevic, D., 
Burant, C., Covinsky, K.E., 2008. Recovery of activities of daily living in older adults 
after hospitalization for acute medical illness. J. Am. Geriatr. Soc. 56, 2171–2179. 
Camacho-Pereira, J., Tarrago, M.G., Chini, C.C.S., Nin, V., Escande, C., Warner, G.M., 
Puranik, A.S., Schoon, R.A., Reid, J.M., Galina, A., Chini, E.N., 2016. CD38 dictates 
age-related NAD decline and mitochondrial dysfunction through an SIRT3-Dependent 
mechanism. Cell Metab. 23, 1127–1139. 
Campisi, J., Kapahi, P., Lithgow, G.J., Melov, S., Newman, J.C., Verdin, E., 2019. From 
discoveries in ageing research to therapeutics for healthy ageing. Nature 571, 
183–192. 
Canto, C., Menzies, K.J., Auwerx, J., 2015. NAD(+) metabolism and the control of energy 
homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22, 
31–53. 
Carri, M.T., D’Ambrosi, N., Cozzolino, M., 2017. Pathways to mitochondrial dysfunction 
in ALS pathogenesis. Biochem. Biophys. Res. Commun. 483, 1187–1193. 
Chan, E.M., Shibue, T., McFarland, J.M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., 
McPartlan, J.S., Li, T., Zhang, Y., Bin Liu, J., Lazaro, J.B., Gu, P., Piett, C.G., Apffel, 
A., Ali, S.O., Deasy, R., Keskula, P., Ng, R.W.S., Roberts, E.A., Reznichenko, E., Leung, 
L., Alimova, M., Schenone, M., Islam, M., Maruvka, Y.E., Liu, Y., Roper, J., Raghavan, 
S., Giannakis, M., Tseng, Y.Y., Nagel, Z.D., D’Andrea, A., Root, D.E., Boehm, J.S., 
Getz, G., Chang, S., Golub, T.R., Tsherniak, A., Vazquez, F., Bass, A.J., 2019. WRN 
helicase is a synthetic lethal target in microsatellite unstable cancers. Nature 568, 
551–556. 
Chen, A.C., Martin, A.J., Choy, B., Fernandez-Penas, P., Dalziell, R.A., McKenzie, C.A., 
Scolyer, R.A., Dhillon, H.M., Vardy, J.L., Kricker, A., St George, G., Chinniah, N., 
Halliday, G.M., Damian, D.L., 2015. A phase 3 randomized trial of nicotinamide for 
skin-cancer chemoprevention. N. Engl. J. Med. 373, 1618–1626. 
Cox, L.S., Clancy, D.J., Boubriak, I., Saunders, R.D., 2007. Modeling Werner Syndrome in 
Drosophila melanogaster: hyper-recombination in flies lacking WRN-like exonu-
clease. Ann. N. Y. Acad. Sci. 1119, 274–288. 
Croteau, D.L., Fang, E.F., Nilsen, H., Bohr, V.A., 2017. NAD+ in DNA repair and mi-
tochondrial maintenance. Cell Cycle 16, 491–492. 
Cummings, J., Lee, G., Ritter, A., Zhong, K., 2018. Alzheimer’s disease drug development 
pipeline: 2018. Alzheimers Dement. N. Y. (N Y) 4, 195–214. 
de la Rubia, J.E., Drehmer, E., Platero, J.L., Benlloch, M., Caplliure-Llopis, J., Villaron- 
Casales, C., de Bernardo, N., AlarcOn, J., Fuente, C., Carrera, S., Sancho, D., GarcIa- 
Pardo, P., Pascual, R., JuArez, M., Cuerda-Ballester, M., Forner, A., Sancho-Castillo, 
S., Barrios, C., Obrador, E., Marchio, P., Salvador, R., Holmes, H.E., Dellinger, R.W., 
Guarente, L., Estrela, J.M., 2019. Efficacy and tolerability of EH301 for amyotrophic 
lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. 
Amyotroph Lateral Scler Frontotemporal Degener. 20, 115–122. 
de Picciotto, N.E., Gano, L.B., Johnson, L.C., Martens, C.R., Sindler, A.L., Mills, K.F., Imai, 
S., Seals, D.R., 2016. Nicotinamide mononucleotide supplementation reverses vas-
cular dysfunction and oxidative stress with aging in mice. Aging Cell 15, 522–530. 
de Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartigues, J.F., Baldereschi, M., 
Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C., Hofman, A., 2000. 
Prevalence of Parkinson’s disease in Europe: a collaborative study of population- 
based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, 
S21–3. 
Demarest, T.G., Babbar, M., Okur, M.N., dan, X., Croteau, D.L., Fakouri, N.B., Mattson, 
M.P., Bohr, V.A., 2019. NAD+ metabolism in aging and Cancer. Annu. Rev. Cancer 
Biol. 3, 105–130. 
Dickson, D.W., 2012. Parkinson’s disease and Parkinsonism: neuropathology. Cold Spring 
Harb. Perspect. Med. 2. 
Diguet, N., Trammell, S.A.J., Tannous, C., Deloux, R., Piquereau, J., Mougenot, N., Gouge, 
A., Gressette, M., Manoury, B., Blanc, J., Breton, M., Decaux, J.F., Lavery, G.G., 
Baczko, I., Zoll, J., Garnier, A., Li, Z., Brenner, C., Mericskay, M., 2018. Nicotinamide 
riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. 
Circulation 137, 2256–2273. 
Dolle, C., Flones, I., Nido, G.S., Miletic, H., Osuagwu, N., Kristoffersen, S., Lilleng, P.K., 
Larsen, J.P., Tysnes, O.B., Haugarvoll, K., Bindoff, L.A., Tzoulis, C., 2016. Defective 
mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. Nat. 
Commun. 7, 13548. 
Dolle, C., Niere, M., Lohndal, E., Ziegler, M., 2010. Visualization of subcellular NAD pools 
and intra-organellar protein localization by poly-ADP-ribose formation. Cell. Mol. 
Life Sci. 67, 433–443. 
Dollerup, O.L., Christensen, B., Svart, M., Schmidt, M.S., Sulek, K., Ringgaard, S., 
Stodkilde-Jorgensen, H., Moller, N., Brenner, C., Treebak, J.T., Jessen, N., 2018. A 
randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: 
safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 108, 
343–353. 
Dollerup, O.L., Chubanava, S., Agerholm, M., Sondergard, S.D., Altintas, A., Moller, A.B., 
Hoyer, K.F., Ringgaard, S., Stodkilde-Jorgensen, H., Lavery, G.G., Barrès, R., Larsen, 
S., Prats, C., Jessen, N., Treebak, J.T., 2019. Nicotinamide riboside does not alter 
mitochondrial respiration, content or morphology in skeletal muscle from obese and 
insulin-resistant men. J. Physiol. 
Ear, P.H., Chadda, A., Gumusoglu, S.B., Schmidt, M.S., Vogeler, S., Malicoat, J., Kadel, J., 
Moore, M.M., Migaud, M.E., Stevens, H.E., Brenner, C., 2019. Maternal nicotinamide 
riboside enhances postpartum weight loss, juvenile offspring development, and 
neurogenesis of adult offspring. Cell Rep. 26 (969–983), e4. 
Fang, E.F., 2019. Mitophagy and NAD(+) inhibit Alzheimer disease. Autophagy 15, 
1112–1114. 
Fang, E.F., Bohr, V.A., 2017. NAD+: the convergence of DNA repair and mitophagy. 
Autophagy 13, 442–443. 
Fang, E.F., Hou, Y., Lautrup, S., Jensen, M.B., Yang, B., SenGupta, T., Caponio, D., Khezri, 
R., Demarest, T.G., Aman, Y., Figueroa, D., Morevati, M., Lee, H.J., Kato, H., 
Kassahun, H., Lee, J.H., Filippelli, D., Okur, M.N., Mangerich, A., L., C.D, Maezawa, 
Y., Lyssiotis, C.A., Tao, J., Yokote, K., Rusten, T.E., Mattson, M.P., Jasper, H., Nilsen, 
H., Bohr, V.A., 2019a. NAD+ augmentation restores mitophagy and limits ac-
celerated aging in Werner syndrome. Nat. Commun. 10, 1–17. 
Fang, E.F., Hou, Y., Palikaras, K., Adriaanse, B.A., Kerr, J.S., Yang, B., Lautrup, S., Hasan- 
Olive, M.M., Caponio, D., Dan, X., Rocktaschel, P., Croteau, D.L., Akbari, M., Greig, 
N.H., Fladby, T., Nilsen, H., Cader, M.Z., Mattson, M.P., Tavernarakis, N., Bohr, V.A., 
2019b. Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive 
deficits in models of Alzheimer’s disease. Nat. Neurosci. 22, 401–412. 
Fang, E.F., Kassahun, H., Croteau, D.L., Scheibye-Knudsen, M., Marosi, K., Lu, H., 
Shamanna, R.A., Kalyanasundaram, S., Bollineni, R.C., Wilson, M.A., Iser, W.B., 
Wollman, B.N., Morevati, M., Li, J., Kerr, J.S., Lu, Q., Waltz, T.B., Tian, J., Sinclair, 
D.A., Mattson, M.P., Nilsen, H., Bohr, V.A., 2016a. NAD(+) replenishment improves 
lifespan and Healthspan in Ataxia telangiectasia models via Mitophagy and DNA 
B.C. Gilmour, et al.   Mechanisms of Ageing and Development 186 (2020) 111208
5
repair. Cell Metab. 24, 566–581. 
Fang, E.F., Lautrup, S., Hou, Y., Demarest, T.G., Croteau, D.L., Mattson, M.P., Bohr, V.A., 
2017. NAD(+) in aging: molecular mechanisms and translational implications. 
Trends Mol. Med. 23, 899–916. 
Fang, E.F., Nilsen, H.L., J., S.-M, Bergersen, L.H., 2019c. NO-age in Norway. Transl. Med. 
Aging 3, 37–39. 
Fang, E.F., Scheibye-Knudsen, M., Brace, L.E., Kassahun, H., SenGupta, T., Nilsen, H., 
Mitchell, J.R., Croteau, D.L., Bohr, V.A., 2014. Defective mitophagy in XPA via PARP- 
1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 157, 882–896. 
Fang, E.F., Scheibye-Knudsen, M., Chua, K.F., Mattson, M.P., Croteau, D.L., Bohr, V.A., 
2016b. Nuclear DNA damage signalling to mitochondria in ageing. Nat. Rev. Mol. 
Cell Biol. 17, 308–321. 
Fang, E.F., Scheibye-Knudsen, M., Jahn, H.J., Li, J., Ling, L., Guo, H., Zhu, X., Preedy, V., 
Lu, H., Bohr, V.A., Chan, W.Y., Liu, Y., Ng, T.B., 2015. A research agenda for aging in 
China in the 21st century. Ageing Res. Rev. 24, 197–205. 
Flones, I.H., Fernandez-Vizarra, E., Lykouri, M., Brakedal, B., Skeie, G.O., Miletic, H., 
Lilleng, P.K., Alves, G., Tysnes, O.B., Haugarvoll, K., Dolle, C., Zeviani, M., Tzoulis, 
C., 2018. Neuronal complex I deficiency occurs throughout the Parkinson’s disease 
brain, but is not associated with neurodegeneration or mitochondrial DNA damage. 
Acta Neuropathol. 135, 409–425. 
Frederick, D.W., Loro, E., Liu, L., Davila Jr., A., Chellappa, K., Silverman, I.M., Quinn 3rd, 
W.J., Gosai, S.J., Tichy, E.D., Davis, J.G., Mourkioti, F., Gregory, B.D., Dellinger, 
R.W., Redpath, P., Migaud, M.E., Nakamaru-Ogiso, E., Rabinowitz, J.D., Khurana, 
T.S., Baur, J.A., 2016. Loss of NAD homeostasis leads to progressive and reversible 
degeneration of skeletal muscle. Cell Metab. 24, 269–282. 
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., Zetterberg, H., 2019. 
Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. 
Neurosurg. Psychiatry 90, 870–881. 
Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., White, 
J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., Mercken, E.M., Palmeira, C.M., de 
Cabo, R., Rolo, A.P., Turner, N., Bell, E.L., Sinclair, D.A., 2013. Declining NAD(+) 
induces a pseudohypoxic state disrupting nuclear-mitochondrial communication 
during aging. Cell 155, 1624–1638. 
Harlan, B.A., Pehar, M., Killoy, K.M., Vargas, M.R., 2019. Enhanced SIRT6 activity ab-
rogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. 
FASEB J fj201802752R. 
Harlan, B.A., Pehar, M., Sharma, D.R., Beeson, G., Beeson, C.C., Vargas, M.R., 2016. 
Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes ex-
pressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1). 
J. Biol. Chem. 291, 10836–10846. 
Hermans, G., Van Mechelen, H., Clerckx, B., Vanhullebusch, T., Mesotten, D., Wilmer, A., 
Casaer, M.P., Meersseman, P., Debaveye, Y., Van Cromphaut, S., 2014. Acute out-
comes and 1-Year mortality of intensive care unit–acquired weakness. A cohort study 
and propensity-matched analysis. Am. J. Respir. Crit. Care Med. 190, 410–420. 
Hou, Y., Lautrup, S., Cordonnier, S., Wang, Y., Croteau, D.L., Zavala, E., Zhang, Y., 
Moritoh, K., O’Connell, J.F., Baptiste, B.A., Stevnsner, T.V., Mattson, M.P., Bohr, V.A., 
2018. NAD(+) supplementation normalizes key Alzheimer’s features and DNA da-
mage responses in a new AD mouse model with introduced DNA repair deficiency. 
Proc. Natl. Acad. Sci. U. S. A. 115, E1876–E1885. 
Iwashyna, T.J., Ely, E.W., Smith, D.M., Langa, K.M., 2010. Long-term cognitive impair-
ment and functional disability among survivors of severe sepsis. JAMA 304, 
1787–1794. 
Kennedy, B.K., Berger, S.L., Brunet, A., Campisi, J., Cuervo, A.M., Epel, E.S., Franceschi, 
C., Lithgow, G.J., Morimoto, R.I., Pessin, J.E., Rando, T.A., Richardson, A., Schadt, 
E.E., Wyss-Coray, T., Sierra, F., 2014. Geroscience: linking aging to chronic disease. 
Cell 159, 709–713. 
Kerr, J.S., Adriaanse, B.A., Greig, N.H., Mattson, M.P., Cader, M.Z., Bohr, V.A., Fang, E.F., 
2017. Mitophagy and Alzheimer’s disease: cellular and molecular mechanisms. 
Trends Neurosci. 40, 151–166. 
Lautrup, S., Caponio, D., Cheung, H.H., Piccoli, C., Stevnsner, T., Chan, W.Y., Fang, E.F., 
2019a. Studying Werner syndrome to elucidate mechanisms and therapeutics of 
human aging and age-related diseases. Biogerontology 20, 255–269. 
Lautrup, S., Lou, G., Aman, Y., Nilsen, H., Tao, J., Fang, E.F., 2019b. Microglial mito-
phagy mitigates neuroinflammation in Alzheimer’s disease. Neurochem. Int. 129, 
104469. 
Lautrup, S., Sinclair, D.A., Mattson, M.P., Fang, E.F., 2019c. NAD+ in brain ageing and 
neurodegenerative disorders. Cell Metab. 30, 630–655. 
Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., 2013. The hallmarks 
of aging. Cell 153, 1194–1217. 
Luo, X., Kraus, W.L., 2012. On PAR with PARP: cellular stress signaling through poly 
(ADP-ribose) and PARP-1. Genes Dev. 26, 417–432. 
Martens, C.R., Denman, B.A., Mazzo, M.R., Armstrong, M.L., Reisdorph, N., McQueen, 
M.B., Chonchol, M., Seals, D.R., 2018. Chronic nicotinamide riboside supplementa-
tion is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. 
Nat. Commun. 9, 1286. 
Mills, K.F., Yoshida, S., Stein, L.R., Grozio, A., Kubota, S., Sasaki, Y., Redpath, P., Migaud, 
M.E., Apte, R.S., Uchida, K., Yoshino, J., Imai, S.I., 2016. Long-term administration of 
nicotinamide mononucleotide mitigates age-associated physiological decline in mice. 
Cell Metab. 24, 795–806. 
Mitchell, S.J., Bernier, M., Aon, M.A., Cortassa, S., Kim, E.Y., Fang, E.F., Palacios, H.H., 
Ali, A., Navas-Enamorado, I., Di Francesco, A., Kaiser, T.A., Waltz, T.B., Zhang, N., 
Ellis, J.L., Elliott, P.J., Frederick, D.W., Bohr, V.A., Schmidt, M.S., Brenner, C., 
Sinclair, D.A., Sauve, A.A., Baur, J.A., de Cabo, R., 2018. Nicotinamide improves 
aspects of healthspan, but not lifespan, in mice. Cell Metab. 27 (667–676), e4. 
Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto, C., Mottis, 
A., Jo, Y.S., Viswanathan, M., Schoonjans, K., Guarente, L., Auwerx, J., 2013. The 
NAD(+)/Sirtuin pathway modulates longevity through activation of mitochondrial 
UPR and FOXO signaling. Cell 154, 430–441. 
Nacarelli, T., Lau, L., Fukumoto, T., Zundell, J., Fatkhutdinov, N., Wu, S., Aird, K.M., 
Iwasaki, O., Kossenkov, A.V., Schultz, D., Noma, K.I., Baur, J.A., Schug, Z., Tang, 
H.Y., Speicher, D.W., David, G., Zhang, R., 2019. NAD(+) metabolism governs the 
proinflammatory senescence-associated secretome. Nat. Cell Biol. 21, 397–407. 
Nakken, O., Lindstrom, J.C., Tysnes, O.B., Holmoy, T., 2016. Mortality trends of amyo-
trophic lateral sclerosis in Norway 1951-2014: an age-period-cohort study. J. Neurol. 
263, 2378–2385. 
Oshima, J., Sidorova, J.M., Monnat Jr., R.J., 2017. Werner syndrome: clinical features, 
pathogenesis and potential therapeutic interventions. Ageing Res. Rev. 33, 105–114. 
Partridge, L., Deelen, J., Slagboom, P.E., 2018. Facing up to the global challenges of 
ageing. Nature 561, 45–56. 
Rubinsztein, D.C., Marino, G., Kroemer, G., 2011. Autophagy and aging. Cell 146, 
682–695. 
Santidrian, A.F., Matsuno-Yagi, A., Ritland, M., Seo, B.B., LeBoeuf, S.E., Gay, L.J., Yagi, 
T., Felding-Habermann, B., 2013. Mitochondrial complex I activity and NAD 
+/NADH balance regulate breast cancer progression. J. Clin. Invest. 123, 
1068–1081. 
Scheibye-Knudsen, M., Mitchell, S.J., Fang, E.F., Iyama, T., Ward, T., Wang, J., Dunn, 
C.A., Singh, N., Veith, S., Hasan-Olive, M.M., Mangerich, A., Wilson, M.A., Mattson, 
M.P., Bergersen, L.H., Cogger, V.C., Warren, A., Le Couteur, D.G., Moaddel, R., 
Wilson 3rd, D.M., Croteau, D.L., de Cabo, R., Bohr, V.A., 2014. A high-fat diet and 
NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 
20, 840–855. 
Schondorf, D.C., Ivanyuk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., 
Giunta, I., Schwarz, L.K., Di Napoli, G., Panagiotakopoulou, V., Nestel, S., Keatinge, 
M., Pruszak, J., Bandmann, O., Heimrich, B., Gasser, T., Whitworth, A.J., Deleidi, M., 
2018. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and 
neuronal loss in iPSC and fly models of Parkinson’s disease. Cell Rep. 23, 2976–2988. 
Shamanna, R.A., Croteau, D.L., Lee, J.H., Bohr, V.A., 2017. Recent advances in under-
standing Werner syndrome. F1000Res 6, 1779. 
Shamanna, R.A., Lu, H., de Freitas, J.K., Tian, J., Croteau, D.L., Bohr, V.A., 2016. WRN 
regulates pathway choice between classical and alternative non-homologous end 
joining. Nat. Commun. 7, 13785. 
Shiloh, Y., Lederman, H.M., 2017. Ataxia-telangiectasia (A-T): an emerging dimension of 
premature ageing. Ageing Res. Rev. 33, 76–88. 
Shiloh, Y., Ziv, Y., 2013. The ATM protein kinase: regulating the cellular response to 
genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197–210. 
Singh, P.P., Demmitt, B.A., Nath, R.D., Brunet, A., 2019. The genetics of aging: a verte-
brate perspective. Cell 177, 200–220. 
Stromland, O., Niere, M., Nikiforov, A.A., VanLinden, M.R., Heiland, I., Ziegler, M., 2019. 
Keeping the balance in NAD metabolism. Biochem. Soc. Trans. 47, 119–130. 
Takemoto, M., Mori, S., Kuzuya, M., Yoshimoto, S., Shimamoto, A., Igarashi, M., Tanaka, 
Y., Miki, T., Yokote, K., 2013. Diagnostic criteria for Werner syndrome based on 
Japanese nationwide epidemiological survey. Geriatr. Gerontol. Int. 13, 475–481. 
Tang, B.L., 2017. Could sirtuin activities modify ALS onset and progression? Cell. Mol. 
Neurobiol. 37, 1147–1160. 
VanLinden, M.R., Dolle, C., Pettersen, I.K., Kulikova, V.A., Niere, M., Agrimi, G., Dyrstad, 
S.E., Palmieri, F., Nikiforov, A.A., Tronstad, K.J., Ziegler, M., 2015. Subcellular dis-
tribution of NAD+ between cytosol and mitochondria determines the metabolic 
profile of human cells. J. Biol. Chem. 290, 27644–27659. 
VanLinden, M.R., Niere, M., Nikiforov, A.A., Ziegler, M., Dolle, C., 2017. Compartment- 
specific Poly-ADP-Ribose formation as a biosensor for subcellular NAD pools. 
Methods Mol. Biol. 1608, 45–56. 
Verdin, E., 2015. NAD(+) in aging, metabolism, and neurodegeneration. Science 350, 
1208–1213. 
Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming, D.W., Souza- 
Pinto, N.C., Bohr, V.A., Rosenzweig, A., de Cabo, R., Sauve, A.A., Sinclair, D.A., 2007. 
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130, 
1095–1107. 
Yoshino, J., Baur, J.A., Imai, S.I., 2018. NAD(+) intermediates: the biology and ther-
apeutic potential of NMN and NR. Cell Metab. 27, 513–528. 
Yu, C.E., Oshima, J., Fu, Y.H., Wijsman, E.M., Hisama, F., Alisch, R., Matthews, S., 
Nakura, J., Miki, T., Ouais, S., Martin, G.M., Mulligan, J., Schellenberg, G.D., 1996. 
Positional cloning of the Werner’s syndrome gene. Science 272, 258–262. 
Zhang, W., Li, J., Suzuki, K., Qu, J., Wang, P., Zhou, J., Liu, X., Ren, R., Xu, X., Ocampo, 
A., Yuan, T., Yang, J., Li, Y., Shi, L., Guan, D., Pan, H., Duan, S., Ding, Z., Li, M., Yi, F., 
Bai, R., Wang, Y., Chen, C., Yang, F., Li, X., Wang, Z., Aizawa, E., Goebl, A., Soligalla, 
R.D., Reddy, P., Esteban, C.R., Tang, F., Liu, G.H., Belmonte, J.C., 2015. Aging stem 
cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a 
driver of human aging. Science 348, 1160–1163. 
Zhu, X.H., Lu, M., Lee, B.Y., Ugurbil, K., Chen, W., 2015. In vivo NAD assay reveals the 
intracellular NAD contents and redox state in healthy human brain and their age 
dependences. Proc. Natl. Acad. Sci. U. S. A. 112, 2876–2881.  
B.C. Gilmour, et al.   Mechanisms of Ageing and Development 186 (2020) 111208
6
